Nigeria, along with seven other African countries, has initiated a collaborative project aimed at tackling HIV on the continent.
The initiative, titled Bringing Innovation to Clinical and Laboratory Research to End HIV in Africa through New Vaccine Technology (BRILLIANT), focuses on advancing HIV vaccine research and development.
The project seeks to leverage cutting-edge vaccine technologies to accelerate the fight against HIV, with the ultimate goal of achieving a significant reduction in new infections across Africa.
This collaborative effort highlights the continent's commitment to ending the HIV epidemic through innovation and scientific research.
Alash’le Abimiku, the executive director of the International Research Centre of Excellence, Institute of Human Virology (IHVN), disclosed this at a press briefing on Thursday in Abuja.
The theme of the briefing was “HIV Vaccine, Innovation, Science, and Technology Acceleration in Africa (HIV-VISTA) study.”
Ms Abimiku said the countries involved were Nigeria, South Africa, Zambia, Zimbabwe, Tanzania, Uganda, Kenya, and Mozambique.
She said the consortium’s objective is to evaluate HIV vaccine candidates emanating from the continent.